Orchid Pharma reported a 15% increase in revenue for Q1 FY27, reaching INR304 crore, up from INR263 crore in the prior year. Combined gross margin improved by approximately 3 percentage points to 33%. The company detailed progress on its Exblifep and Cefiderocol projects, highlighting international market expansion and strategic partnerships. Management expressed optimism about the combined entity’s platform and future value creation opportunities.
Orchid Pharma Reports Strong Q1 FY27 Performance
Orchid Pharma Limited has announced its financial results for the first quarter of the Financial Year 2027 (Q1 FY27), reporting a significant year-on-year revenue growth and an improvement in gross margins. The company’s revenue from operations increased by 15% to INR304 crore in Q1 FY27, compared to INR263 crore in the corresponding quarter of the previous year. This growth reflects a stronger footing for the financial year 2027. The combined gross margin also saw an improvement of approximately 3 percentage points, reaching 33% in Q1 FY27, up from 30% in Q1 FY26. EBITDA for the quarter improved to INR25 crore, from INR10 crore in Q1 FY26.
Strategic Project Updates and Outlook
The management provided updates on key strategic initiatives, including the progress of Exblifep as a global commercial platform. The company is actively pursuing partnerships in various international markets, with advanced discussions underway for South America, Mexico, Philippines, Thailand, Morocco, and Australia. In Europe, the Exblifep business is showing steady growth, with volumes increasing significantly across quarters. The Cefiderocol project remains on schedule, targeting commissioning by December 2026 and initial batches in early 2027. The 7-ACA project, a critical backward integration initiative, is also progressing towards commissioning by March 2027.
Looking ahead, Orchid Pharma remains focused on protecting and growing its core business through cost discipline, improving product mix, and executing its capital projects. The company anticipates that the benefits from merger synergies and new projects will emerge progressively. The combined Orchid-Dhanuka platform, along with backward integration into 7-ACA and the Cefiderocol access project, is expected to create a more diversified set of value creation opportunities.
Key Financial Highlights (Q1 FY27 vs Q1 FY26)
- Revenue from operations: INR304 crore vs INR263 crore (up 15%)
- Combined Gross Margin: 33% vs 30% (up approx. 3 percentage points)
- EBITDA: INR25 crore vs INR10 crore
The company is also actively managing its AMS (Antimicrobial Stewardship) business, which continues to be managed with financial discipline, and its quarterly EBITDA drag has reduced significantly.
Source: BSE
